| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | tumor necrosis factor receptor superfamily member 17, B-Cell Maturation Antigen, TNFRSF17, CD269 |
| Product Type | |
| Shipping | |
| Species | |
| Storage |
Scientific Background
B-Cell Maturation Antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17) or CD269, is a type I membrane protein encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily, that recognizes its ligands including BAFF (B-cell activating factor) and APRIL (a proliferation inducing ligand). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. In vitro, the activation of BCMA by its ligand promotes the differentiation and proliferation of B cells. A vast array of intracellular activity is involved in BCMA-induced signal transduction, including activation of the NF-κB signaling pathway. The bioactivity of BAFF and APRIL as soluble homotrimers distinguishes them from other TNFSF ligands such as TRAIL, FasL, and CD40L, which are only active as membrane-bound molecules.
Product Description
CAR T-Cell TherapyThe BCMA / NF-κB - HEK293 recombinant cell line has been transfected with full-length human BCMA cDNA (Genbank #NM_001192) under control of a CMV promoter for high constitutive expression. The NF-κB-luciferase reporter is also stably integrated into the genome. The firefly luciferase gene is controlled by four copies of the NF-κB Response Element upstream of a minimal promoter. Upon ligand binding, active BCMA will initiate the NF-κB signaling pathway, leading to expression of the NF-κB-controlled luciferase reporter.
Product Specifications
| Host Cell Line | HEK293 |
|---|---|
| Host Species | Human |
| Transfection Method | Lipofectamine 2000 |
| Supplied As | Two vials containing ~ 2 x 106 cells in 1 ml of 10% DMSO in FBS |
| Harmonized Tariff Code | 3002-5900 |
Quality Control & Validation
✓ Mycoplasma-TestedThis cell line has been screened using the Venor™ GeM Mycoplasma Detection Kit, PCR Based (Sigma, #MP0025) to confirm the absence of Mycoplasma contamination.
Safety & Handling
⚠ Avoid multiple freeze/thaw cycles.
Regulatory Information
License Disclosure
Related Products
Related Products: Cat. #90187-A, 79528, 60690, 79718, 100254, 79796
Required Accessories: Cat. #60187,79528,79796,60690
This product is engineered on a HEK293 background (Human origin). The HEK293 host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.
This product is classified as BSL-2. Work must be performed in a certified BSL-2 laboratory by trained personnel. All procedures that may generate aerosols must be conducted inside a Class II Biological Safety Cabinet. Institutional Biosafety Committee (IBC) approval is required before use.
Yes. This cell line has been screened using the Venor™ GeM Mycoplasma Detection Kit, PCR Based (Sigma, #MP0025) to confirm the absence of Mycoplasma contamination. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.
Store this product at Liquid Nitrogen. Specifically: Store in liquid nitrogen immediately upon receipt. Do not store long-term at -80°C or on dry ice. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.
Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.
This stable cell line was generated using Lipofectamine 2000 for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.
Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:
- Cell line sourcing and selection (species, tissue, and disease model matching)
- Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
- Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
- Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
- Inducible expression systems (Tet-On/Off and regulatable constructs)
- Drug resistance marker selection (puromycin, G418, hygromycin, and others)
- Custom growth and media optimisation for specific assay requirements
- Scale-up production for high-throughput screening campaigns
- Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)
Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Hahne, M. et al. (1998) J. Exp. Med. 188:1185.
- Yu, G. et al. (2000) Nat. Immunol. 1:252.
- Yan, M. et al. (2000) Nat. Immunol. 1:37.
- Gravestein, L.A. and Borst, J. (1998) Sem. Immunol. 10:423.
